{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:00:24Z","timestamp":1791165624038,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04889-7","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:47:00Z","timestamp":1778590020000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oxaliplatin-associated nephrotoxicity: clinical patterns, renal pharmacokinetics, and mechanistic insights"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3286-567X","authenticated-orcid":false,"given":"Ananya","family":"Chetia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momita Rani","family":"Baro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-4213","authenticated-orcid":false,"given":"Manas","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"issue":"1","key":"4889_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3747\/co.v18i1.708","volume":"18","author":"Thierry Alcindor","year":"2011","unstructured":"Alcindor T, Beauger N (2011) Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 18(1):18\u201325 https:\/\/doi.org\/10.3747\/co.v18i1.708","journal-title":"Current Oncology"},{"issue":"4","key":"4889_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/rcm.4408","volume":"24","author":"A Bouslimani","year":"2010","unstructured":"Bouslimani A, Bec N, Glueckmann M, Hirtz C, Larroque C (2010) Matrix-assisted laser desorption\/ionization imaging mass spectrometry of oxaliplatin derivatives in heated intraoperative chemotherapy (HIPEC)-like treated rat kidney. Rapid Commun Mass Spectrometry: RCM 24(4):415\u2013421. https:\/\/doi.org\/10.1002\/rcm.4408","journal-title":"Rapid Commun Mass Spectrometry: RCM"},{"issue":"2","key":"4889_CR3","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5414\/CN109131","volume":"89","author":"Y-J Choi","year":"2018","unstructured":"Choi Y-J, Oh K-H, Kang H-R, Lee S-J (2018) Oxaliplatin-induced acute tubulointerstitial nephritis: Two case reports. Clin Nephrol 89(2):130\u2013134. https:\/\/doi.org\/10.5414\/CN109131","journal-title":"Clin Nephrol"},{"issue":"3","key":"4889_CR4","doi-asserted-by":"publisher","first-page":"e36549","DOI":"10.7759\/cureus.36549","volume":"15","author":"R Choudhary","year":"2023","unstructured":"Choudhary R, Bundela MK, Bharang K (2023) Comparison of Renal Functions Evaluated by Measured Glomerular Filtration Rate in Patients Treated With Cisplatin, Carboplatin, and Oxaliplatin. Cureus 15(3):e36549. https:\/\/doi.org\/10.7759\/cureus.36549","journal-title":"Cureus"},{"issue":"4","key":"4889_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/0964-1955(95)00082-8","volume":"32B","author":"M Degardin","year":"1996","unstructured":"Degardin M, Cappelaere P, Krakowski I, Fargeot P, Cupissol D, Brienza S (1996) Phase II trial of oxaliplatin (L-OHP) in advanced, recurrent and\/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 32B(4):278\u2013279. https:\/\/doi.org\/10.1016\/0964-1955(95)00082-8","journal-title":"Eur J Cancer"},{"issue":"2","key":"4889_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/jat\/32.2.140","volume":"32","author":"D Esteban-Fernandez","year":"2008","unstructured":"Esteban-Fernandez D, Verdaguer JM, Ramirez-Camacho R, Palacios MA, Gomez-Gomez MM (2008) Accumulation, Fractionation, and Analysis of Platinum in Toxicologically Affected Tissues after Cisplatin, Oxaliplatin, and Carboplatin Administration. J Anal Toxicol 32(2):140\u2013146. https:\/\/doi.org\/10.1093\/jat\/32.2.140","journal-title":"J Anal Toxicol"},{"issue":"4","key":"4889_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/BF00684890","volume":"25","author":"JM Extra","year":"1990","unstructured":"Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25(4):299\u2013303. https:\/\/doi.org\/10.1007\/BF00684890","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4889_CR8","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1002\/hsr2.479","volume":"5","author":"ARDS Fernandes","year":"2022","unstructured":"Fernandes ARDS, de Brito GA, Baptista AL, Andrade LAS, Imanishe MH, Pereira BJ (2022) The influence of acute kidney disease on the clinical outcomes of patients who received cisplatin, carboplatin, and oxaliplatin. Health Sci Rep 5(1):e479. https:\/\/doi.org\/10.1002\/hsr2.479","journal-title":"Health Sci Rep"},{"issue":"1","key":"4889_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/ckj\/sft148","volume":"7","author":"N Filewod","year":"2014","unstructured":"Filewod N, Lipman ML (2014) Severe acute tubular necrosis observed subsequent to oxaliplatin administration. Clin Kidney J 7(1):68\u201370. https:\/\/doi.org\/10.1093\/ckj\/sft148","journal-title":"Clin Kidney J"},{"issue":"7","key":"4889_CR10","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/sj.bjc.6600185","volume":"86","author":"JL Fischel","year":"2002","unstructured":"Fischel JL, Formento P, Ciccolini J, Rostagno P, Etienne MC, Catalin J, Milano G (2002) Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity. Br J Cancer 86(7):1162\u20131168. https:\/\/doi.org\/10.1038\/sj.bjc.6600185","journal-title":"Br J Cancer"},{"key":"4889_CR11","doi-asserted-by":"publisher","first-page":"105179","DOI":"10.1016\/j.tiv.2021.105179","volume":"75","author":"H Fujishiro","year":"2021","unstructured":"Fujishiro H, Taguchi H, Hamao S, Sumi D, Himeno S (2021) Comparisons of segment-specific toxicity of platinum-based agents and cadmium using S1, S2, and S3 cells derived from mouse kidney proximal tubules. Toxicol Vitro: Int J Published Association BIBRA 75:105179. https:\/\/doi.org\/10.1016\/j.tiv.2021.105179","journal-title":"Toxicol Vitro: Int J Published Association BIBRA"},{"issue":"3","key":"4889_CR12","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.1016\/j.ekir.2020.02.585","volume":"5","author":"S Gupta","year":"2020","unstructured":"Gupta S, Abdulbaki A, Hijazi F, Lascano M, Ghosn M, Attallah N, Madhyastha R, Malik A (2020) SUN-060 Late presentation of nephrotoxicity due to oxaliplatin. Kidney Int Rep 5(3):S228. https:\/\/doi.org\/10.1016\/j.ekir.2020.02.585","journal-title":"Kidney Int Rep"},{"issue":"19","key":"4889_CR13","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1200\/JCO.22.02759","volume":"41","author":"RM Goldberg","year":"2023","unstructured":"Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR (2023) A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer. J Clin Oncol 41(19):3461\u20133468. https:\/\/doi.org\/10.1200\/JCO.22.02759","journal-title":"J Clin Oncol"},{"issue":"4","key":"4889_CR14","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clcc.2014.09.003","volume":"13","author":"S Gori","year":"2014","unstructured":"Gori S, Lunardi G, Inno A, Magarotto R, Duranti S, Messa MG, Mucchino C, Cirillo M (2014) Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis. Clin Colorectal Cancer 13(4):260\u2013263. https:\/\/doi.org\/10.1016\/j.clcc.2014.09.003","journal-title":"Clin Colorectal Cancer"},{"issue":"9","key":"4889_CR15","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s11095-010-0189-4","volume":"27","author":"K Hanada","year":"2010","unstructured":"Hanada K, Suda M, Kanai N, Ogata H (2010) Pharmacokinetics and Toxicodynamics of Oxaliplatin in Rats: Application of a Toxicity Factor to Explain Differences in the Nephrotoxicity and Myelosuppression Induced by Oxaliplatin and the Other Platinum Antitumor Derivatives. Pharm Res 27(9):1893\u20131899. https:\/\/doi.org\/10.1007\/s11095-010-0189-4","journal-title":"Pharm Res"},{"issue":"2","key":"4889_CR16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/23993693221150371","volume":"7","author":"PE Hanna","year":"2023","unstructured":"Hanna PE, Borgi L, Schlechter BL (2023) Recovery of dialysis-dependent acute kidney injury after cessation of oxaliplatin. J Onco-Nephrology 7(2):66\u201369. https:\/\/doi.org\/10.1177\/23993693221150371","journal-title":"J Onco-Nephrology"},{"key":"4889_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.5152\/turkjnephrol.2021.4434","volume":"30","author":"E Haziyev","year":"2021","unstructured":"Haziyev E, Gursu M, Seker M, Elcioglu O, Artan A, Aliyev A, Turk H, Demir T, Toprak A, Kazancioglu R (2021) Evaluation of Kidney Function in Patients on Chemotherapy. Turkish J Nephrol 30:138\u2013144. https:\/\/doi.org\/10.5152\/turkjnephrol.2021.4434","journal-title":"Turkish J Nephrol"},{"issue":"1","key":"4889_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s00280-011-1633-9","volume":"68","author":"T Horimatsu","year":"2011","unstructured":"Horimatsu T, Miyamoto S, Morita S, Mashimo Y, Ezoe Y, Muto M, Chiba T (2011) Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol 68(1):263\u2013266. https:\/\/doi.org\/10.1007\/s00280-011-1633-9","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4889_CR19","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s10157-012-0620-8","volume":"16","author":"I Ito","year":"2012","unstructured":"Ito I, Ito Y, Mizuno M, Suzuki Y, Yasuda K, Ozaki T, Kosugi T, Yasuda Y, Sato W, Tsuboi N, Maruyama S, Imai E, Matsuo S (2012) A rare case of acute kidney injury associated with autoimmune hemolytic anemia and thrombocytopenia after long-term usage of oxaliplatin. Clin Exp Nephrol 16(3):490\u2013494. https:\/\/doi.org\/10.1007\/s10157-012-0620-8","journal-title":"Clin Exp Nephrol"},{"issue":"3","key":"4889_CR20","doi-asserted-by":"publisher","first-page":"363","DOI":"10.4103\/0019-509X.176696","volume":"52","author":"A Jain","year":"2015","unstructured":"Jain A, Dubashi B, Parameswaran S, Ganesh RN (2015) Oxaliplatin induced acute tubular necrosis. Indian J Cancer 52(3):363. https:\/\/doi.org\/10.4103\/0019-509X.176696","journal-title":"Indian J Cancer"},{"issue":"2","key":"4889_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1124\/jpet.111.181297","volume":"338","author":"NN Jong","year":"2011","unstructured":"Jong NN, Nakanishi T, Liu JJ, Tamai I, McKeage MJ (2011) Oxaliplatin Transport Mediated by Organic Cation\/Carnitine Transporters OCTN1 and OCTN2 in Overexpressing Human Embryonic Kidney 293 Cells and Rat Dorsal Root Ganglion Neurons. J Pharmacol Exp Ther 338(2):537\u2013547. https:\/\/doi.org\/10.1124\/jpet.111.181297","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"4889_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1177\/1060028014526160","volume":"48","author":"AY Joybari","year":"2014","unstructured":"Joybari AY, Sarbaz S, Azadeh P, Mirafsharieh SA, Rahbari A, Farasatinasab M, Mokhtari M (2014) Oxaliplatin-induced renal tubular vacuolization. Annals Pharmacotherapy 48(6):796\u2013800. https:\/\/doi.org\/10.1177\/1060028014526160","journal-title":"Annals Pharmacotherapy"},{"issue":"9","key":"4889_CR23","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.3390\/ijms22094618","volume":"22","author":"J Jagie\u0142a","year":"2021","unstructured":"Jagie\u0142a J, Bartnicki P, Rysz J (2021) Nephrotoxicity as a Complication of Chemotherapy and Immunotherapy in the Treatment of Colorectal Cancer, Melanoma and Non-Small Cell Lung Cancer. Int J Mol Sci 22(9):4618. https:\/\/doi.org\/10.3390\/ijms22094618","journal-title":"Int J Mol Sci"},{"key":"4889_CR24","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4137\/cmo.s412","volume":"2","author":"K Katsumata","year":"2008","unstructured":"Katsumata K, Sumi T, Wada T, Mori Y, Hisada M, Kawakita H, Enomoto M, Suzuki S, Matsuda D, Tsuchida A, Aoki T (2008) Oxaliplatin for metastatic colon cancer in a patient with renal failure. Clin Med Oncol 2:97\u2013101. https:\/\/doi.org\/10.4137\/cmo.s412","journal-title":"Clin Med Oncol"},{"issue":"6","key":"4889_CR25","first-page":"1153","volume":"37","author":"H Kawazoe","year":"2010","unstructured":"Kawazoe H, Kawazoe H, Sugishita H, Watanabe S, Tanaka A, Morioka J, Suemaru K, Watanabe Y, Kawachi K, Araki H (2010) [Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment]. Gan Kagaku Ryoho Cancer Chemother 37(6):1153\u20131157","journal-title":"Gan Kagaku Ryoho Cancer Chemother"},{"issue":"5","key":"4889_CR26","first-page":"637","volume":"71","author":"Y Kidani","year":"1980","unstructured":"Kidani Y, Noji M, Tashiro T (1980) Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers. Gan 71(5):637\u2013643","journal-title":"Gan"},{"issue":"6","key":"4889_CR27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/BF00685038","volume":"31","author":"R Kizu","year":"1993","unstructured":"Kizu R, Higashi S, Kidani Y, Miyazaki M (1993) Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol 31(6):475\u2013480. https:\/\/doi.org\/10.1007\/BF00685038","journal-title":"Cancer Chemother Pharmacol"},{"issue":"24","key":"4889_CR28","doi-asserted-by":"publisher","first-page":"6382","DOI":"10.3390\/cancers13246382","volume":"13","author":"S Kobuchi","year":"2021","unstructured":"Kobuchi S, Kai M, Ito Y (2021) Population Pharmacokinetic Model-Based Evaluation of Intact Oxaliplatin in Rats with Acute Kidney Injury. Cancers 13(24):6382. https:\/\/doi.org\/10.3390\/cancers13246382","journal-title":"Cancers"},{"key":"4889_CR29","doi-asserted-by":"publisher","unstructured":"Kouma E, Emamaddin G, Almalki A (2021) Severe AKI induced by Oxaliplatin: A case report. Int J Med Developing Ctries 1. https:\/\/doi.org\/10.24911\/IJMDC.51-1634904046","DOI":"10.24911\/IJMDC.51-1634904046"},{"issue":"3","key":"4889_CR30","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.bbamcr.2014.12.033","volume":"1853","author":"K Kr\u00fcger","year":"2015","unstructured":"Kr\u00fcger K, Thomale J, Stojanovi\u0107 N, Osmak M, Henninger C, Bormann S, Fritz G (2015) Platinum-induced kidney damage: Unraveling the DNA damage response (DDR) of renal tubular epithelial and glomerular endothelial cells following platinum injury. Biochim et Biophys Acta (BBA) - Mol Cell Res 1853(3):685\u2013698. https:\/\/doi.org\/10.1016\/j.bbamcr.2014.12.033","journal-title":"Biochim et Biophys Acta (BBA) - Mol Cell Res"},{"issue":"1","key":"4889_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1620\/tjem.245.21","volume":"245","author":"S Kato","year":"2018","unstructured":"Kato S, Imai H, Gamoh M, Takahata T, Ohori H, Yasuda K, Niitani T, Murakawa Y, Amagai K, Isobe H, Shindo Y, Kuroki M, Sakamoto Y, Shimodaira H, Yoshioka T, Ishioka C (2018) Intermittent Withdrawal of Oxaliplatin for Alleviating Neurotoxicity during Oxaliplatin-Based Chemotherapy for Japanese Patients with Inoperable or Metastatic Colorectal Cancer: A Phase 2 Multicenter Study. Tohoku J Exp Med 245(1):21\u201328. https:\/\/doi.org\/10.1620\/tjem.245.21","journal-title":"Tohoku J Exp Med"},{"issue":"6","key":"4889_CR32","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1093\/ndt\/gfh826","volume":"20","author":"J Labaye","year":"2005","unstructured":"Labaye J, Sarret D, Duvic C, H\u00e9rody M, Didelot F, N\u00e9d\u00e9lec G, No\u00ebl L-H (2005) Renal toxicity of Oxaliplatin. Nephrol Dialysis Transplantation 20(6):1275\u20131276. https:\/\/doi.org\/10.1093\/ndt\/gfh826","journal-title":"Nephrol Dialysis Transplantation"},{"key":"4889_CR33","doi-asserted-by":"publisher","unstructured":"Lee EM (2024) Acute oxaliplatin-induced immune hemolytic anemia and thrombocytopenia; a case of oxaliplatin immune-induced syndrome. J Oncol Res Therapy 9:10253. https:\/\/doi.org\/10.29011\/2574-710X.10253","DOI":"10.29011\/2574-710X.10253"},{"issue":"9","key":"4889_CR34","first-page":"873","volume":"41","author":"B Legallicier","year":"1993","unstructured":"Legallicier B, Leclere C, Monteil C, Morin JP, Fillastre JP (1993) [Toxic effect of two antitumoral agents derived from platinum, the cisplatin and the oxaliplatin on primary cultures of proximal tubular cells of the kidney in rabbits]. Pathol Biol 41(9):873\u2013880","journal-title":"Pathol Biol"},{"issue":"9","key":"4889_CR35","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/0959-8049(93)90073-o","volume":"29A","author":"F Levi","year":"1993","unstructured":"Levi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, Zidani R, Brienza S, Itzhaki M, Iacobelli S (1993) Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer (Oxford England: 1990) 29A(9):1280\u20131284. https:\/\/doi.org\/10.1016\/0959-8049(93)90073-o","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"issue":"4","key":"4889_CR36","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/annonc\/mdm080","volume":"18","author":"M Linch","year":"2007","unstructured":"Linch M, Cunningham D, Mingo O, Stiles A, Farquhar-Smith WP (2007) Renal tubular acidosis due to oxaliplatin. Annals Oncology: Official J Eur Soc Med Oncol 18(4):805\u2013806. https:\/\/doi.org\/10.1093\/annonc\/mdm080","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"19","key":"4889_CR37","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.3390\/molecules27196485","volume":"27","author":"RL Lucaciu","year":"2022","unstructured":"Lucaciu RL, Hangan AC, Sevastre B, Oprean LS (2022) Metallo-Drugs in Cancer Therapy: Past, Present and Future. Molecules 27(19):6485. https:\/\/doi.org\/10.3390\/molecules27196485","journal-title":"Molecules"},{"key":"4889_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186250","author":"Paola Marmiroli","year":"2017","unstructured":"Marmiroli P, Riva B, Pozzi E, Ballarini E, Lim D, Chiorazzi A, Meregalli C, Distasi C, Renn CL, Semperboni S, Morosi L, Ruffinatti FA, Zucchetti M, Dorsey SG, Cavaletti G, Genazzani A, Carozzi VA (2017) Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights. PloS One 12(10):e0186250. https:\/\/doi.org\/10.1371\/journal.pone.0186250","journal-title":"Plos One"},{"issue":"3","key":"4889_CR39","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s10147-015-0911-7","volume":"21","author":"C Matsuda","year":"2016","unstructured":"Matsuda C, Honda M, Tanaka C, Fukunaga M, Ishibashi K, Munemoto Y, Hata T, Bando H, Oshiro M, Kobayashi M, Tokunaga Y, Fujii A, Nagata N, Oba K, Mishima H (2016) Multicenter randomized phase II clinical trial of oxaliplatin reintroduction as a third- or later-line therapy for metastatic colorectal cancer\u2014Biweekly versus standard triweekly XELOX (The ORION Study). Int J Clin Oncol 21(3):566\u2013572. https:\/\/doi.org\/10.1007\/s10147-015-0911-7","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"4889_CR40","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s11255-012-0177-1","volume":"45","author":"E M\u00e1rquez","year":"2013","unstructured":"M\u00e1rquez E, Rodr\u00edguez E, Pascual J (2013) Inadvertent severe acute kidney injury and oxaliplatin. Int Urol Nephrol 45(1):297\u2013298. https:\/\/doi.org\/10.1007\/s11255-012-0177-1","journal-title":"Int Urol Nephrol"},{"issue":"2","key":"4889_CR41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s002800050024","volume":"45","author":"C Massari","year":"2000","unstructured":"Massari C, Brienza S, Rotarski M, Gastiaburu J, Misset JL, Cupissol D, Alafaci E, Dutertre-Catella H, Bastian G (2000) Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 45(2):157\u2013164. https:\/\/doi.org\/10.1007\/s002800050024","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4889_CR42","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0753-3322(89)90003-6","volume":"43","author":"G Math\u00e9","year":"1989","unstructured":"Math\u00e9 G, Kidani Y, Segiguchi M, Eriguchi M, Fredj G, Peytavin G, Misset JL, Brienza S, De Vassals F, Chenu E, Bourut C (1989) Oxalato-platinum or 1-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother 43(4):237\u2013250. https:\/\/doi.org\/10.1016\/0753-3322(89)90003-6","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"4889_CR43","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00216-016-9327-0","volume":"408","author":"I Moraleja","year":"2016","unstructured":"Moraleja I, Esteban-Fern\u00e1ndez D, L\u00e1zaro A, Humanes B, Neumann B, Tejedor A, Mena ML, Jakubowski N, G\u00f3mez-G\u00f3mez MM (2016) Printing metal-spiked inks for LA-ICP-MS bioimaging internal standardization: Comparison of the different nephrotoxic behavior of cisplatin, carboplatin, and oxaliplatin. Anal Bioanal Chem 408(9):2309\u20132318. https:\/\/doi.org\/10.1007\/s00216-016-9327-0","journal-title":"Anal Bioanal Chem"},{"issue":"7","key":"4889_CR44","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"issue":"2","key":"4889_CR45","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1248\/bpb.b22-00578","volume":"46","author":"S Nakagawa","year":"2023","unstructured":"Nakagawa S, Shimazaki A, Funakoshi T, Yonezawa A, Kataoka S, Horimatsu T, Hira D, Itohara K, Imai S, Nakagawa T, Matsubara T, Yanagita M, Muto M, Matsubara K, Terada T (2023) Effect of Severe Renal Dysfunction on the Plasma Levels of DNA-Reactive Platinum after Oxaliplatin Administration. Biol Pharm Bull 46(2):194\u2013200. https:\/\/doi.org\/10.1248\/bpb.b22-00578","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"4889_CR46","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00280-014-2667-6","volume":"75","author":"M Nikanjam","year":"2015","unstructured":"Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, Capparelli EV (2015) Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemother Pharmacol 75(3):495\u2013503. https:\/\/doi.org\/10.1007\/s00280-014-2667-6","journal-title":"Cancer Chemother Pharmacol"},{"key":"4889_CR47","doi-asserted-by":"publisher","unstructured":"Osawa H (2016) Oxaliplatin Pharmacokinetics and Pharmacodynamics in Three Metastatic Colorectal Cancer Patients with Hemodialysis. J Mol Genet Med 10. https:\/\/doi.org\/10.4172\/1747-0862.1000234","DOI":"10.4172\/1747-0862.1000234"},{"key":"4889_CR48","doi-asserted-by":"publisher","unstructured":"Oun R, Moussa Y E, Wheate N J(2018) The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans 47:6645\u20136653 https:\/\/doi.org\/10.1039\/C8DT00838H","DOI":"10.1039\/C8DT00838H"},{"key":"4889_CR49","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Reviews 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Reviews"},{"key":"4889_CR50","doi-asserted-by":"publisher","unstructured":"Page MJ et al (2021) BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"issue":"3","key":"4889_CR51","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1093\/ndtplus\/sfp008","volume":"2","author":"NT Phan","year":"2009","unstructured":"Phan NT, Heng AE, Lautrette A, K\u00e9m\u00e9ny JL, Souweine B (2009) Oxaliplatin-induced acute renal failure presenting clinically as thrombotic microangiopathy: Think of acute tubular necrosis. NDT Plus 2(3):254\u2013256. https:\/\/doi.org\/10.1093\/ndtplus\/sfp008","journal-title":"NDT Plus"},{"issue":"2","key":"4889_CR52","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/j.clcc.2016.11.005","volume":"16","author":"P Phull","year":"2017","unstructured":"Phull P, Quillen K, Hartshorn KL (2017) Acute Oxaliplatin-induced Hemolytic Anemia, Thrombocytopenia, and Renal Failure: Case Report and a Literature Review. Clin Colorectal Cancer 16(2):e105\u2013e107. https:\/\/doi.org\/10.1016\/j.clcc.2016.11.005","journal-title":"Clin Colorectal Cancer"},{"issue":"12","key":"4889_CR53","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1093\/annonc\/mdf311","volume":"13","author":"G Pinotti","year":"2002","unstructured":"Pinotti G, Martinelli B (2002) A case of acute tubular necrosis due to oxaliplatin. Annals Oncology: Official J Eur Soc Med Oncol 13(12):1951\u20131952. https:\/\/doi.org\/10.1093\/annonc\/mdf311","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"10","key":"4889_CR54","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1039\/c3mt00147d","volume":"5","author":"O Reifschneider","year":"2013","unstructured":"Reifschneider O, Wehe CA, Raj I, Ehmcke J, Ciarimboli G, Sperling M, Karst U (2013) Quantitative bioimaging of platinum in polymer embedded mouse organs using laser ablation ICP-MS. Metallomics: Integr biometal Sci 5(10):1440\u20131447. https:\/\/doi.org\/10.1039\/c3mt00147d","journal-title":"Metallomics: Integr biometal Sci"},{"issue":"8","key":"4889_CR55","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.3390\/biomedicines9081033","volume":"9","author":"S Schoch","year":"2021","unstructured":"Schoch S, Sen V, Brenner W, Hartwig A, K\u00f6berle B (2021) In Vitro Nephrotoxicity Studies of Established and Experimental Platinum-Based Compounds. Biomedicines 9(8):1033. https:\/\/doi.org\/10.3390\/biomedicines9081033","journal-title":"Biomedicines"},{"issue":"1","key":"4889_CR56","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12882-023-03116-2","volume":"24","author":"Y Soma","year":"2023","unstructured":"Soma Y, Kawabe T, Kitaji D, Hoshino K, Sunohara S, Iwano T, Kawano N (2023) Biopsy-proven first dose of oxaliplatin-induced acute tubular necrosis leading to end-stage renal failure: A case report. BMC Nephrol 24(1):76. https:\/\/doi.org\/10.1186\/s12882-023-03116-2","journal-title":"BMC Nephrol"},{"key":"4889_CR57","doi-asserted-by":"publisher","unstructured":"Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Yamaguchi T (2015) Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 3099. https:\/\/doi.org\/10.2147\/DDDT.S85567","DOI":"10.2147\/DDDT.S85567"},{"issue":"4","key":"4889_CR58","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1039\/b907567d","volume":"1","author":"RC Todd","year":"2009","unstructured":"Todd RC, Lippard SJ (2009) Inhibition of transcription by platinum antitumor compounds. Metallomics 1(4):280. https:\/\/doi.org\/10.1039\/b907567d","journal-title":"Metallomics"},{"issue":"12","key":"4889_CR59","first-page":"1899","volume":"25","author":"T Taguchi","year":"1998","unstructured":"Taguchi T, Tsukagoshi S, Furue H, Niitani H, Noda K (1998) [Phase I clinical study of oxaliplatin]. Gan Kagaku Ryoho Cancer Chemother 25(12):1899\u20131907","journal-title":"Gan Kagaku Ryoho Cancer Chemother"},{"issue":"16","key":"4889_CR60","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1158\/1078-0432.CCR-07-0475","volume":"13","author":"CH Takimoto","year":"2007","unstructured":"Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, Remick SC, Sharma S, Mani S, Ramanathan RK, Synold TW, Doroshow JH, Hamilton A, Mulkerin DL, Ivy P, Egorin MJ, Grem JL (2007) Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function. Clin Cancer Res 13(16):4832\u20134839. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0475","journal-title":"Clin Cancer Res"},{"issue":"14","key":"4889_CR61","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1200\/JCO.2003.11.015","volume":"21","author":"CH Takimoto","year":"2003","unstructured":"Takimoto CH, Remick SC, Sharma S, Mani S, Ramanathan RK, Doroshow J, Hamilton A, Mulkerin D, Graham M, Lockwood GF, Ivy P, Egorin M, Schuler B, Greenslade D, Goetz A, Knight R, Thomas R, Monahan BP, Dahut W, National Cancer Institute Organ Dysfunction Working Group Study (2003) Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: A National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncology: Official J Am Soc Clin Oncol 21(14):2664\u20132672. https:\/\/doi.org\/10.1200\/JCO.2003.11.015","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"10","key":"4889_CR62","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1248\/bpb.b25-00361","volume":"48","author":"T Tanaka","year":"2025","unstructured":"Tanaka T, Tanaka A, Kobuchi S, Ito Y, Sakaeda T (2025) Association of Plasma Creatinine with Systemic Exposure to S-1 and Oxaliplatin in Two Types of Chronic Kidney Disease Animal Models. Biol Pharm Bull 48(10):1493\u20131502. https:\/\/doi.org\/10.1248\/bpb.b25-00361","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"4889_CR63","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s12032-009-9263-3","volume":"27","author":"A Ulusakarya","year":"2010","unstructured":"Ulusakarya A, Misra S, Haydar M, Habert H, Castagne V, Gumus Y, Delmas-Marsalet B, Machover D (2010) Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med Oncol (Northwood Lond Engl) 27(4):1425\u20131426. https:\/\/doi.org\/10.1007\/s12032-009-9263-3","journal-title":"Med Oncol (Northwood Lond Engl)"},{"issue":"4","key":"4889_CR64","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/jcpt.12661","volume":"43","author":"IRF van Berlo","year":"2018","unstructured":"van Berlo IRF, Brummelhuis WJ, Imholz ALT, Schellens JH, Huitema ADR, Jansman FGA (2018) Dosing oxaliplatin in a haemodialysis patient with metastatic rectum cancer monitored by free platinum concentrations. J Clin Pharm Ther 43(4):574\u2013577. https:\/\/doi.org\/10.1111\/jcpt.12661","journal-title":"J Clin Pharm Ther"},{"issue":"44","key":"4889_CR65","doi-asserted-by":"publisher","first-page":"e17462","DOI":"10.1097\/MD.0000000000017462","volume":"98","author":"D Wang","year":"2019","unstructured":"Wang D, Li X, Xu L, Fang W, Cai X, Wang Y, Wang J, Wang Y, Zhao F, Gu Y (2019) Dose-escalation of oxaliplatin in hemodialysis patient treated with FOLFOX therapy. Medicine 98(44):e17462. https:\/\/doi.org\/10.1097\/MD.0000000000017462","journal-title":"Medicine"},{"issue":"1","key":"4889_CR66","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40880-015-0061-3","volume":"35","author":"Z-Q Wang","year":"2016","unstructured":"Wang Z-Q, Zhang D-S, Xu N, Luo D-Y, Deng Y-H, Wang F-H, Luo H-Y, Qiu M-Z, Li Y-H, Xu R-H (2016) Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer. Chin J Cancer 35(1):8. https:\/\/doi.org\/10.1186\/s40880-015-0061-3","journal-title":"Chin J Cancer"},{"issue":"1","key":"4889_CR67","doi-asserted-by":"publisher","first-page":"299","DOI":"10.21873\/anticanres.13953","volume":"40","author":"D Watanabe","year":"2020","unstructured":"Watanabe D, Fujii H, Yamada Y, Iihara H, Ishihara T, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A (2020) Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin. Anticancer Res 40(1):299\u2013304. https:\/\/doi.org\/10.21873\/anticanres.13953","journal-title":"Anticancer Res"},{"issue":"4","key":"4889_CR68","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/jjco\/hyp176","volume":"40","author":"Y Watayo","year":"2010","unstructured":"Watayo Y, Kuramochi H, Hayashi K, Nakajima G, Kamikozuru H, Yamamoto M (2010) Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis. Jpn J Clin Oncol 40(4):360\u2013364. https:\/\/doi.org\/10.1093\/jjco\/hyp176","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"4889_CR69","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s13730-019-00390-8","volume":"8","author":"S Yamada","year":"2019","unstructured":"Yamada S, Yazawa M, Yamamoto M, Koitabashi K, Ichikawa D, Koike J, Shibagaki Y (2019) A case of biopsy-proven oxaliplatin-induced acute tubulointerstitial nephritis with thrombocytopenia and anemia. CEN Case Rep 8(3):188\u2013193. https:\/\/doi.org\/10.1007\/s13730-019-00390-8","journal-title":"CEN Case Rep"},{"issue":"2","key":"4889_CR70","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/jjco\/hyz149","volume":"50","author":"K Yamazaki","year":"2020","unstructured":"Yamazaki K, Matsumoto S, Imamura CK, Yamagiwa C, Shimizu A, Yoshino T (2020) Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: A multicenter post-marketing surveillance study. Jpn J Clin Oncol 50(2):122\u2013128. https:\/\/doi.org\/10.1093\/jjco\/hyz149","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"4889_CR71","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3390\/cimb47030172","volume":"47","author":"T Ye","year":"2025","unstructured":"Ye T, Wu C, Na J, Liu X, Huang Y (2025) Multi-Pathway Study for Oxaliplatin Resistance Reduction. Curr Issues Mol Biol 47(3):172. https:\/\/doi.org\/10.3390\/cimb47030172","journal-title":"Curr Issues Mol Biol"},{"issue":"2","key":"4889_CR72","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1124\/jpet.106.110346","volume":"319","author":"A Yonezawa","year":"2006","unstructured":"Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K (2006) Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319(2):879\u2013886. https:\/\/doi.org\/10.1124\/jpet.106.110346","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"4889_CR73","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.bcp.2010.11.016","volume":"81","author":"A Yonezawa","year":"2011","unstructured":"Yonezawa A, Inui K (2011) Organic cation transporter OCT\/SLC22A and H(+)\/organic cation antiporter MATE\/SLC47A are key molecules for nephrotoxicity of platinum agents. Biochem Pharmacol 81(5):563\u2013568. https:\/\/doi.org\/10.1016\/j.bcp.2010.11.016","journal-title":"Biochem Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04889-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04889-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04889-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:47:02Z","timestamp":1778590022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04889-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4889"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04889-7","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this article is a review of previously published studies and does not involve human participants or animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}